摘要
目的探讨ⅢB～Ⅳ期非小细胞肺癌(NSCLC)患者癌组织内核苷酸切除修复交叉互补组1(ERCC1)基因的表达与含铂类的化疗方案敏感性的关系。方法入选病理学证实为ⅢB～Ⅳ期NSCLC患者31例,化疗前采用反转录-聚合酶链反应法检测其组织学标本ERCC1mRNA的表达水平。患者均接受至少2个周期的含铂类的化疗方案化疗,对患者化疗后的总生存期、肿瘤进展时间及化疗后反应率进行评价。结果 ERCC1 mRNA高表达者化疗后反应率、总生存期、肿瘤进展时间为41%、8.8个月及5.8个月,ERCC1 mRNA低表达者为86%、13.7个月及8.6个月,差异均有统计学意义(P<0.05)。结论 ERCC1 mRNA表达水平是评估晚期NSCLC患者应用铂类药物化疗疗效的一个重要因素。
Objective To study the relationship between mRNA expression level of excision repair cross-complementation group1（ERCC1） and the effect of platinum-based chemotherapy in patients with stage ⅢB-Ⅳ non-small cell lung cancer（NSCLC）.Methods Thirty-one patients,who were diagnosed as NSCLC by the pathologic examination with percutaneous needle aspiration or fibrobronchoscopy biopsy,were enrolled.The relative quantitative expression of ERCC1 mRNA in histological specimens was examined by using RT-PCR before chemotherapy.All patients received two cycles of platinum-based chemotherapy.The overall survival（OS）,the time to progression（TTP） and the response rate（RR） were evaluated.Results The high expression rate of ERCC1 mRNA of all the 31 patients was 54.8%.After chemotherapy,the RR,OS,and TTP were 41%,8.8 months,and 5.8 months in the high expression group,respectively,Those were 86%,13.7 months,and 8.6 months in the low expression group,respectively.The difference between the two groups was significant（P0.05）.Conclusion The expression level of ERCC1 mRNA might be an important factor of evaluating the effects of platinum-based chemotherapy in ⅢB-Ⅳ NSCLC patients.
出处
《医学综述》
2010年第23期3669-3670,共2页
Medical Recapitulate
